|
Thursday 3 November 2011 |
| |
|
| 13.00 |
Welcome and
introduction |
| |
|
| 13.30-18.00 |
Strategies for
organ preservation |
| |
Chairs: Jean
Louis Lefebvre, Jean Bourhis |
| 13.30 |
Strategies for larynx preservation |
| |
Jean Louis
Lefebvre, France |
| 14.00 |
Partial laryngeal
surgery |
| |
Dominique
Chevalier, France |
| 14.20 |
Salvage surgery
after chemo-radiotherapy |
| |
Miquel Quer,
Spain |
| 14.40 |
Is modern imaging able to predict response to
treatment (before, during)? |
| |
Sandra Nuyts,
Belgium |
| 15.00 |
Proffered Papers |
| |
Chairs: Jean Louis Lefebvre, Jean Bourhis |
| 15.00 |
Boron neutron capture therapy for recurrent head and neck cancer |
| |
Itsuro Kato, Osaka, Japan |
| 15.15 |
Intensity modulated radiotherapy for head & neck cancer- Is
there a correlation between mean contralateral parotid dose and
objective late oral toxicity? |
| |
David McIntosh, Glasgow, United Kingdom |
| 15.30 |
Recurrence patterns and salvage surgery following chemoradiation
for advanced laryngeal and hypopharyngeal carcinoma |
| |
Simone Eerenstein, Amsterdam, The Netherlands |
| 15.45 |
Cetuximab plus radiotherapy versus concomitant cisplatin plus
radiotherapy, a randomised study |
| |
Caroline Brammer, Wolverhampton, United Kingdom |
| |
|
| 16.00 |
Coffee break |
| |
|
| 16.30 |
Clinical Cases |
| |
Moderator: Jean
Bourhis, France |
| 17.30 |
Debate on organ preservation:
Alternating chemotherapy / radiation therapy |
| |
Marco Merlano,
Italy |
| |
versusConcurrent chemotherapy / radiation
therapy |
| |
Kian Ang, USA |
| |
|
| Friday 4 November
2011 |
| |
|
| 9.00-12.30 |
Rare head and neck tumors |
| |
Chairs: Jan Vermorken, Philip
Sloan |
| 9.00 |
Translational research in rare
tumors |
| |
Philip Sloan, UK |
| 9.20 |
Salivary gland carcinoma |
| |
Lisa Licitra, Italy |
| 9.40 |
Sinonasal cancers: progress,
challenges and future directions |
| |
Ehab Hanna, USA |
| 10.00 |
Proffered Papers |
| |
Chairs: Jan Vermorken, Philip
Sloan |
| 10.00 |
Salivary gland carcinoma in Denmark 1990-2005: Incidence,
histology, outcome and prognostic factors. Results of the Danish
Head and Neck Cancer Group (DAHANCA |
| |
Kristine Bjørndal, Odense, Denmark |
| 10.20 |
Multi-slice Computed Tomography Angiography in evaluation of
neck tumor vascular pattern and value of spread with in neck
structures |
| |
Liana Gzirishvili, Tbilisi, Georgia |
| |
|
| 10.40 |
Coffee break |
| |
|
| 11.15 |
Advances in radiotherapy of rare
head and neck cancer |
| |
Hans Langendijk, The
Netherlands |
| 11.30 |
Advances in the treatment of
head and neck melanoma |
| |
Ulrich Keilholz, Germany |
| 11.45 |
Clinical cases |
| |
Moderator: Jan Vermorken |
| |
|
| 12.30-13.45 |
Satellite Symposium – Merck
Serono |
| |
Chairs:
Jean Louis Lefebvre, France and Francesco Cognetti, Italy |
| 12.30 |
Welcome and introduction |
| |
Francesco Cognetti, Italy |
| 12.35 |
Optimizing RT treatment for patients with locally advanced Head
and Neck tumors |
| |
Moderator: Jean Louis Lefebvre |
| |
Speakers:
Jean Bourhis, France
Marco Merlano, Italy
Kian Ang, USA
Andreas Dietz, Germany |
| 13.05 |
Optimizing 1st line treatment for patients with r/m
Head and Neck tumors |
| |
Moderator: Jan Vermorken |
| |
Speakers:
Lisa Licitra, Italy
Sandrine Favre, France
Ulrich Keilholz, Germany |
| 13.35 |
Conclusions |
| |
Jean Louis Lefebvre, France |
| |
|
| 12.30 |
Lunch break |
| |
|
| 13.45-18.00 |
Strategies for non-resectable
tumors |
| |
Chairs: René Leemans, Andreas
Dietz |
| 13.45 |
Keynote Lecture |
| |
René Leemans, The Netherlands |
| 14.15 |
How to manage the residual
disease? |
| |
Andreas Dietz, Germany |
| 14.35 |
Is there a place for maintenance
therapy? |
| |
Sandrine Faivre, France |
| 14.55 |
Are all non resectable diseases to be treated in
the same way? |
| |
Jan Vermorken, Belgium |
| 15.15 |
Proffered Papers |
| |
Chairs: René Leemans, Andreas Dietz |
| 15.15 |
Weekly multiagent chemotherapy for advanced non melanoma skin
cancer |
| |
Vittoria Espeli, Geneva, Switzerland |
| 15.30 |
Quality of life in patients with head and neck cancer: Can we
predict patients whose quality of life will deteriorate most
during the acute toxicity phase of radiotherapy? |
| |
Silke Tribius, Hamburg, Germany |
| 15.45 |
Serial comprehensive geriatric evaluation in elderly head and
neck cancer patients undergoing radiotherapy |
| |
Philip Debruyne, Kortrijk, Belgium |
| 16.00 |
A randomized, open-label, phase II study of afatinib (BIBW 2992)
versus cetuximab in recurrent or metastatic squamous cell
carcinoma of the head and neck |
| |
Tanguy
Seiwert, Chicago, USA |
| |
|
| 16.15 |
Coffee break |
| |
|
| 16.45 |
Clinical Cases |
| |
Moderator: Andreas Dietz |
| 17.30 |
Debate:
Induction chemotherapy |
| |
Jan Vermorken, Belgium |
| |
versus
Concurrent chemo-radiation therapy |
| |
Volker Budach, Germany |
| |
|
| Saturday 5
November 2011 |
| |
|
| 9.00-12.30 |
Virus-induced head and neck
tumors |
| |
Chairs: Kian Ang, Amanda
Psyrri |
| 9.00 |
Nasopharyngeal carcinoma (NPC) |
| |
Lisa Licitra, Italy |
| 9.30 |
Human Papilloma Virus (HPV)
related head & neck cancers |
| |
Amanda Psyrri, USA |
| 9.50 |
Immunotherapy and vaccination |
| |
t.b.c. |
| 10.10 |
Psychosocial aspects in head and
neck cancer patients |
| |
Gerry Humphris, UK |
| |
|
| 10.30 |
Coffee break |
| |
|
| 11.00 |
Proffered papers |
| |
Chairs: Kian Ang, Amanda
Psyrri |
| 11.00 |
Relationship between Epstein Barr Virus markers and prognostic
in nasopharyngeal carcinoma |
| |
Esma Kerboua, Alger, Algeria |
| 11.20 |
Induction TP followed by concomitant chemoradiation versus RT/cetuximab
chemoradiation in locally advanced nasopharyngeal carcinoma:
Initial results of a randomized phase II study |
| |
Guopei Zhu, Shanghai, China |
| |
|
| 11.40 |
Clinical Cases |
| |
Moderator: Kian Ang, USA |
| |
|
| 12.30 |
Closing |
| |
|